HUNTINGTON STATION, NY--(MARKET WIRE)--Jul 24, 2008 -- Medivisor Inc. (Other OTC:MVSR.PK - News) today announced that it has signed a new sales and marketing agreement with Cura Pharmaceutical for the marketing of Mucotrol(TM) in the United States. The groundbreaking drug Mucotrol(TM) is an oral gel wafer that received 510-K approval as a device from the FDA in late November 2004, as a treatment for mouth sores related to chemotherapy.
Cura will supply and distribute Mucotrol(TM) with Medivisor handling the marketing and sales. Under the terms of the new agreement both parties agree to now share in the net profits.
"We are pleased to have signed this new sales and marketing agreement with Cura," stated Dino Luzzi, CEO of Medivisor. "We believe Mucotrol will demonstrate strong commercial interest in the relief of side effects of those patients undergoing chemotherapy treatments."
About Medivisor Inc.: Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy and market research.
About Cura Pharmaceutical: Cura is a privately held pharmaceutical business that develops, distributes and sells innovative and generic pharmaceuticals. It focuses on selected niche specialty markets through the offering of distinctive products and services, which provide distinct unmet medical needs.
About Mucotrol(TM): Mucotrol(TM) is prescribed for the management and relief of pain for Mucositis, which may be caused by chemotherapy or radiotherapy and irritation due to oral surgery. The National Cancer Institute estimates that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments.
Aug 2006 Medivisor enters Media Partnership Agreement with ACI Communications Active Communications International, Inc. (ACI) is a leader in conference planning and production. ACI produces world-class events in many business segments including Cardiac Services, Women's Health, Neuroscience, Sports Medicine and Orthopedic Services. Together, Medivisor and ACI's combined media power has the potential to reach thousands of online Physicians for the upcoming Adding, Updating and Expanding Competitive Bariatric Surgery Servicesonline conference held on September 14, 2006 - September 15, 2006. Implementing Successful Bariatric Surgery Programs and Service Lines to Meet the Patient Demand, Increase Market Share and Enhance Revenue. Studies over the past 30 years have found obesity sharply on the rise in U.S. adults, with little sign of decline and approximately 65 percent of Americans being overweight. With the combination of population statistics, minimal start up capital, increased public awareness, celebrity endorsement, favorable out-of-pocket payments and insurers starting to see the long-term health benefits, most hospitals are willing to make the necessary investments in implementing and updating bariatric surgery programs to enhance their reputation and build revenue while addressing a critical health need in their communities. Some of the key findings include:
• Obesity-related medical conditions contribute to 300,000 deaths per year, the second highest cause of preventable death.
• Bariatric surgical market is $3 billion and is expected to grow to $3.7 billion by 2008.
• The specialized products area is expected to increase with the obesity market, as bariatric beds alone will increase between 22% and 27% in the next few years.
To prepare hospitals for growth opportunities in bariatric medicine, ACI has developed the Premiere National Conference on Adding, Updating and Expanding Competitive BARIATRIC SURGERY SERVICES For Hospitals and Health Centers.
ACI is dedicated to producing high-quality, strategic business conferences where audience members, speakers, and sponsors develop key industry contacts and walk away with new knowledge and resources.
Langen Pharmaceutical grants the rights to distribute Mucotrol in Israel and Italy
As of May 2006 Medivisor was granted the exclusive rights to distribute, promote, and sell Mucotrol in the countries of Israel and Italy in its entirety. Entering into this agreement Medivisor has the right to appoint any sub-distributor to distribute, market, and/or sell Mucotrol. Mucotrol is for the relief of pain by mucositis/stomatitis, which may be caused by chemotherapy or radiotherapy.
Medivisor Inc. and Cura Pharmaceutical Sign Marketing Agreement for Mucotrol™ Huntington Station, NY., February 28, 2006 – announced today that it has entered into a marketing agreement with Cura Pharmaceutical Co., Inc., a New Jersey based pharmaceutical marketing company, to distribute, promote and sell Mucotrol™ concentrated oral gel wafer for the management and relief of pain from oral lesions associated with oral mucositis/stomatitis in the United States. According to the terms of the agreement, Cura will distribute and sell Mucotrol(TM) while Medivisor will market the product. Dino Luzzi, Medivisor's CEO, commented: "We are excited by the potential of this agreement. Cura's management has extensive experience in the oncology market and has achieved significant market share in the products it has introduced. Medivisor’s marketing plan calls to leverage its expertise to market Mucotrol™ to hospitals with major oncology centers across the country as well as larger private oncology practices and other secondary markets."
The National Cancer Institute estimates that approximately 300,000 cancer patients in the United States suffer from mucositis associated with cancer treatments.
About Medivisor Inc.
Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor designs and presents interactive, informational, video and high tech animated graphic presentations for medical industry to view at Medivisor's interactive website, always at a time and place chosen by the healthcare professional. Additionally, advanced technology is utilized to create a variety of educational and informational formats with immediate tracking capabilities.
About Cura Pharmceutical Co.
Cura Pharmaceutical Co., Inc. is a New Jersey based pharmaceutical marketing company that focuses in selected niche specialty markets through the offering of distinctive products and services, which provide distinct unmet medical needs, efficiency and/or cost effectiveness, products not readily accessible, as well as products that enhance existing treatments.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, further events or otherwise.
CONTACT:
Medivisor Inc.
Dino Luzzi, CEO
631-549-7100
For more information visit: http://www.medivisor.com/
Medivisor's Internet Conferencing joins the fight against cancer. Medivisor hosted participation of the 2004 International Conference on Cancer on the Internet.
The Internet is the cornerstone of the techno-cultural revolution that is starting to transform the nature of cancer control. Patients have been at the forefront of this revolution and many are now regularly using the Internet to obtain information about their disease and its treatment, seek support from on-line patient communities and support groups, share knowledge and experiences with other patients and to communicate with their professional careers and loved ones. There is a great deal of confusion and many concerns as to the quality and appropriateness of online patient resources; however, it is impossible to police the Internet. In order to address these concerns, many governmental and non-governmental organizations have developed guidelines for quality health Websites and on evaluating health information on the Internet. Unfortunately, implementation of these guidelines has been patchy. Moreover, there is little or no government protection for e-consumers of health sites particularly in terms of privacy, security and confidentiality.
The Internet provides an important tool to facilitate clinical practice and cancer research. Professional access to and use of content and Internet applications is an essential part of providing appropriate cancer care, for more information, please register at Statdose.com
2004 International Conference on Cancer on the Internet September 13-14, 2004
Rockefeller University, New York City
Organized by the European School of Oncology and the
American-Italian Cancer Foundation
For a free cd-rom copy of the 2004 conference please email: cbush@medivisor.com
DOCSBACKOFFICE.COM JOINS FORCES WITH MEDIVISOR.
Lake Success, N.Y. (November 5, 2002) - Medivisor.com, the Huntington Station, New York based e-detailing medical communication company, announces that it has signed a multi-year affiliation agreement to co-brand its website with Docsbackoffice.com. Medivisor.com provides an Internet based detailing services for pharmaceutical companies to deliver their information to practicing medical professionals. Docsbackoffice.com, Inc., Internet portal provides vital business-to-business services to assist doctors' medical practices to operate more efficiently and profitably.
Richard Ventimiglia, President of Docsbackoffice.com said, "We are looking forward to a long-term and mutually beneficial relationship between the two companies. The strategies of the companies are completely complementary. I have confidence that physicians' using the Docsbackoffice.com website will value the convenience and information of online pharmaceutical detailing powered by Medisivor.com."
Medivisor will power the e-detailing information services under the new agreement. Wayne Wertheim, M.D., Executive Vice President of Medivisor, says of the new agreement, "Docsbackoffice.com's primary focus upon building and servicing private physician and practice relationships makes it an ideal distribution partner for Medivisor and its sister site StatDose.com. Our approach to deliver quality medical information is optimal for delivery through this distribution agreement with DocsbackOffice.com.
Medivisor was founded in 1998 and maintains its corporate headquarters in Huntington Station, New York. Medivisor is a full service medical communication company servicing the pharmaceutical arena in delivering "detailing" messages to healthcare providers. Membership of physicians to their sister site, StatDose.com, entitles them to be notified of online programs in fields of interest to them. The site also provides many value added services to it's thousands of physician members. It is through the StatDose portal that Medivisor will introduce the value of this affiliation to its members.
Founded in 1999 and headquartered in Lake Success, NY, Docsbackoffice will enhance the doctor's practice, or "back office" operations, by providing a full-range of services that will include: e-commerce, financial tracking, and operations consulting. The key to improving collections, cash flow and operations is in better management of staff personnel. Docsbackoffice's Online Consultant™ provides the doctor with an effective method to better managed the key financial function of the practice for less than $85 per month.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Interested parties are cautioned that such statements are only predictions and that actual events or results may differ materially. Forward-looking statements involve risks and uncertainties, including, but not limited to, the companies' ability to raise sufficient capital to fund its operations, acceptance of the companies' services in the marketplace, competitive factors, new technology, the companies' dependence upon third-parties, and several other risk factors. In evaluating such statements, interested parties should specifically consider the various factors that could cause actual events or results to differ materially from those indicated in such forward-looking statements.
Contact: Wayne H. Wertheim, MD.
Medivisor.com (631) 549.7100
wertheim@medivisor.com
MEDIVISOR.COM IS JUST WHAT THE DOCTOR ORDERED Bay Shore, N.Y., February 22, 2002- Medivisor.com maximizes the effectiveness of communication between pharmaceutical representative and physician, known as detailing, by taking the whole process and putting it on the Internet. The new Medivisor.com website has new features that offer the pharmaceutical and healthcare industries a medium to interface their ideas and thoughts. This is a business "solution" and solutions are remedies to problems. The problems surrounding the pharmaceutical marketplace are those of competition-not just for market share, but also for the doctor's time.
Once a customized pharma marketing program is developed, participating physicians undergo a strict verification process. Medivisor.com delivers concise messages of an informative, educational, promotional, or other nature averaging five to seven minutes in length, with high quality audio, and sophisticated graphics. Statistical evaluations are made based on data that is gathered with the physicians' knowledge and approval. The field representatives make direct responses with this information. With the growing population that has access to the Internet, product information is communicated with maximum impact. Message retrieval can take place anywhere the physician has access to the Internet, at the time that they choose- often when distractions are minimal such as before office hours, at home, in transport, even on the beach! E-detailing with Medivisor.com will empower the pharmaceutical industry and keep pace with today's physicians who must make every minute count.
DINO LUZZI, MEDIVISOR.COM PRESIDENT DISCUSSES HIS SUCCESS FORMULA: e-Detailing and Excellence Although e-Detailing may be a relatively new concept, its success or failure is still determined by traditional marketing criteria -increased revenue, ROI, and share of market. I am committed to Medivisor.com upholding the highest standards of good business practice set long before the Internet was born, and confident in our success. E-Detailing has unlimited potential and far-reaching possibilities.
There is essentially a triumvirate of e-Detailing clients. They are the physician, the pharma company and the sales representative. Medivisor devises pathways of effective communication to reach new levels of efficiency. Our marketing solutions evolve; the constant gathering of data enable us to develop the best client branding and execution of targeted marketing strategies. We are the launch partners to the pharma company and the sales tool of the marketing rep. We provide physicians with updated accurate information, easily accessed in a user- friendly format.
e-Detailing is a way to augment the sales call, not to replace it. It overcomes the limitations of a sales force harnessed by specific restrictions placed upon them by managed care organizations. The sales representative can be obstructed by "no-see" physicians and by rural and vacant territories. All of this adds to the cost of delivering their message and product. Medivisor lowers the cost of effective sales strategies. We start a dialogue with the target audience and optimize market awareness with persuasive product messages delivered consistently and completely.
Time restraints have been lifted. E-detailing has changed the dynamics of the physician/sales representative relationship. The opportunities offered by software, the Internet and wireless solutions maximize Customer Relationship Management (CRM) streamlining the merging and sharing of information. Now customer service, e-business, marketing, sales, medical education, marketing research and regulatory affairs can be found under one umbrella, at Medivisor.com
Change is in the air. You may never again see a sales rep. turned away from a receptionist's desk or flipping through a magazine in a doctor's waiting room, anxious to relate the latest scientific breakthrough offered by their pharma company. Doctors will be rewarded, finding the information and product that they need, at a time most convenient and conducive to interaction. Pharma companies will extend their reach and physicians will be calling on reps for visits and samples as a result of e-Detailing with Medivisor.com. I am thrilled to live in these exciting times and proud of our commitment to excellence.
I am excited to be a catalyst to these changing times and committed to excellence in providing a service that is a win/win situation for all involved.
